A first-in-class monoclonal antibody has shown significant reductions in skin disease in patients with cutaneous lupus erythematosus (CLE). Litifilimab met the primary endpoint of reduction of disease ...
William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s ...
Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE).
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clea ...
Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, Aurinia inked an acquisition and Lilly built its case for Ebglyss.
Biogen Inc. BIIB shares are up on Monday following the FDA’s approval of a new high-dose regimen for Spinraza (nusinersen), a ...
Biogen announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (part A) of investigational therapy, ...
Insilico Medicine signed a large deal with Eli Lilly over AI-driven drug discovery, and there’s a psoriasis race underway.
Litifilimab was superior to placebo for reducing skin disease activity in cutaneous lupus erythematosus, according to phase 2 ...
Anifrolumab treatment is linked to improved disease activity and reduced steroid use and has an acceptable safety profile in routine care of patients with systemic lupus erythematosus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results